SCHEMBL30748960

SCHEMBL30748960

CC(C)C(N)c1ccc(Br)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 2/20 0.36
ADRA2B P18089 2/20 0.36
ADRA2C P18825 2/20 0.36
PLAU P00749 1/20 0.36
GBA1 P04062 1/20 0.36
S1PR3 Q99500 5/20 0.35
S1PR4 O95977 2/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAOA P21397 1/20 0.32
S1PR1 P21453 1/20 0.32
FDPS P14324 1/20 0.32
B3GNT2 Q9NY97 1/20 0.32
MEN1 O00255 1/20 0.31
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
PPARG P37231 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL589541 0.83 ADRA2A (0.38) ADRA2AADRA2BADRA2CPLAUGBA1
SCHEMBL2588895 0.83 ADRA2A (0.38) ADRA2AADRA2BADRA2CPLAUGBA1
SCHEMBL1063041 0.83 ADRA2A (0.38) ADRA2AADRA2BADRA2CPLAUGBA1
Hydrochloric Acid SCHEMBL27772275 0.82 ADRA2A (0.40) ADRA2AADRA2BADRA2CPLAUGBA1
Hydrochloric Acid SCHEMBL14120689 0.82 ADRA2A (0.40) ADRA2AADRA2BADRA2CPLAUGBA1
Hydrochloric Acid SCHEMBL1060426 0.82 ADRA2A (0.40) ADRA2AADRA2BADRA2CPLAUGBA1
Ammonia Solution, Strong SCHEMBL7423037 0.82 ADRA2A (0.37) ADRA2AADRA2BADRA2CPLAUGBA1
Hydrochloric Acid SCHEMBL12802328 0.82 ADRA2A (0.40) ADRA2AADRA2BADRA2CPLAUGBA1
Hydrochloric Acid SCHEMBL14157237 0.82 ADRA2A (0.40) ADRA2AADRA2BADRA2CPLAUGBA1
SCHEMBL681840 0.79 GBA1 (0.41) ADRA2AADRA2BADRA2CPLAUGBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT ADRA2A 3973/4885ADRA2B 4470/4885ADRA2C 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.